PSMA Clinical Trials

18 recruitingLast updated: June 18, 2026

There are 18 actively recruiting psma clinical trials across 15 countries. Studies span Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 3. Top locations include Xi'an, Shaanxi, China, Yan’an, Shaanxi, China, Lanzhou, Gansu, China. Updated daily from ClinicalTrials.gov.


PSMA Trials at a Glance

18 actively recruiting trials for psma are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Xi'an, Yan’an, and Lanzhou. Lead sponsors running psma studies include Xijing Hospital, First Affiliated Hospital of Chongqing Medical University, and Centre Jean Perrin.

Browse psma trials by phase

Treatments under study

About PSMA Clinical Trials

Looking for clinical trials for PSMA? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PSMA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PSMA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 1

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07641049
Recruiting
Not Applicable

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

PSMA PETProstate Cancer Screening
First Affiliated Hospital of Fujian Medical University230 enrolled1 locationNCT06923657
Recruiting
Phase 1

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Bayer198 enrolled35 locationsNCT06217822
Recruiting

Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis

bone metastasisPSMA PETProstate Cancer (Diagnosis)+4 more
Xijing Hospital1,000 enrolled9 locationsNCT07553754
Recruiting

Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer

Treatment ResponseHigh-risk Prostate CancerPSMA PET+1 more
Xijing Hospital110 enrolled9 locationsNCT07553780
Recruiting
Not Applicable

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Lu-177 PSMA
M.D. Anderson Cancer Center25 enrolled1 locationNCT07169825
Recruiting
Not Applicable

68Ga-PSMA PET in the Renal Cell Carcinoma

MetastasesRenal CancerPSMA PET
Xijing Hospital300 enrolled9 locationsNCT04987086
Recruiting

PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

Prostate Cancer MetastaticPSMA Positive Tumors or Tumor Tissues
IRCCS Azienda Ospedaliero-Universitaria di Bologna1,300 enrolled4 locationsNCT07089550
Recruiting
Phase 3

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.370 enrolled1 locationNCT07311694
Recruiting
Not Applicable

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Castration Resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin120 enrolled5 locationsNCT06600802
Recruiting
Phase 3

PSMA PET Combined With MRI for the Detection of PCa

Prostate CancerProstatic NeoplasmPCA+6 more
Telix Pharmaceuticals (Innovations) Pty Limited204 enrolled1 locationNCT07052214
Recruiting
Phase 2

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics60 enrolled9 locationsNCT06549465
Recruiting

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

Prostate CancerMetastasisPositron Emission Tomography+2 more
Tianjin Medical University500 enrolled2 locationsNCT06690970
Recruiting
Early Phase 1

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Positron Emission TomographyFAPPSMA
First Affiliated Hospital of Chongqing Medical University30 enrolled1 locationNCT06387381
Recruiting
Early Phase 1

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

Prostate Cancer StagePSMASPECT
First Affiliated Hospital of Chongqing Medical University30 enrolled1 locationNCT06419348
Recruiting

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital150 enrolled1 locationNCT06850545
Recruiting

PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer

Prostate CancerSurvivorshipPET/CT+1 more
University Hospital, Essen10,000 enrolled1 locationNCT06320223